SUMMARY The efficacy of propranolol and metoprolol in the treatment of essential tremor was compared in a double blind crossover placebo-controlled study in 16 patients. Each treatment was given for a period of 4 weeks at two different dosage regimens (150 and 300 mg daily for metoprolol, 120 and 240 mg daily for propranolol). Each dosage regimen lasted for 2 weeks. Tremor assessment was carried out by accelerometry, clinical evaluation, patient's self-rating and a battery of performance tests. At the lower dosage, propranolol was found to be superior to placebo on the basis of performance tests and patient's self-assessment. At receiving any drug therapy for tremor at the time of the study but nine of them had been previously treated with propranolol (range 80-240 mg daily). Patients with a history of excessive alcohol intake, congestive heart failure, A-V block, diabetes mellitus and asthma were excluded.
The role of fli-selective adrenoceptor antagonists in the symptomatic relief of essential tremor has not been yet clearly established. Following initial reports claiming that metoprolol is effective,`-5 the controlled studies conducted so far with either metoprolol or atenolol have led to conflicting results.68 In some of these studies, however, fi -selective drugs have been compared with non selective 13-adrenoceptor antagonists such as propranolol and sotalol at dosages not having equipotent fl-blocking activity, thus making it difficult to obtain a quantitative assessment of their comparative tremorolytic potencies. This issue has important therapeutic implications because fi,-selective drugs may represent an alternative to propranolol in patients with essential tremor and obstructive disease of the upper airways. In a previous study9 we found that a single oral dose of metoprolol (150 mg) reduced the amplitude of essential tremor to virtually the same extent as a fli-equipotent dose of propranolol (120 mg). This encouraging observation led us to compare the efficacy of these two drugs following prolonged administration in the same population of patients.
Methods

Patients
Sixteen patients affected by moderate to severe essential tremor (eight male and eight female) aged between 20 and 72 years (mean age 43 years) and attending the out patient clinics at the National Hospital for Nervous Diseases, Queen Square, gave their informed consent to participate in the study.
The diagnosis was established on the basis of the clinical history and detailed general and neurological examination accompanied by ancillary laboratory investigations, where 893 necessary. All patients had been symptomatic for at least 1 year (range 1 to 43 years) prior to the study. In nine patients there was a family history of tremor affecting hands or head or both. Fifteen patients had previously taken part in a single oral dose study with the same drugs.9 No patient was receiving any drug therapy for tremor at the time of the study but nine of them had been previously treated with propranolol (range 80-240 mg daily). Patients with a history of excessive alcohol intake, congestive heart failure, A-V block, diabetes mellitus and asthma were excluded.
Protocol
The study was double-blind and consisted of three treatments (metoprolol, propranolol and placebo) arranged according to a crossover design. Each treatment lasted for four weeks. The active treatments consisted of two consecutive periods (each lasting for two weeks) during which two dosage regimens were used: 120 and 240 mg (as 40 or 80 mg tablets) daily for propranolol and 150 and 300 mg (as 50 or 100 mg tablets) daily for metoprolol. These doses are considered, on the basis of literature data, to produce a comparable degree of cardiac fl-blockade. ' The order of treatment was randomised, but within each active treatment period the lower dosage always preceded the higher dosage regimen. Drug (or placebo) were given in three equally divided daily doses. All tablets looked alike and the same number of tablets was taken in any one day of the study.
Assessment of hand tremor was performed at the end of each dosage period (that is every two weeks) as near as possible at the same time of day for each patient. Patients were instructed to take the previous dose about 2 hours before testing. Tremor was measured by means of piezoresistive linear accelerometers attached to the dorsal surface of the outstretched hands, the forearms being supported up to the wrists.9 On each recording session three separate tremor recordings of about 3 min duration were obtained at 5 min intervals. The signal was amplified, recorded on paper and stored on magnetic tape for off-line spectrum analysis. The following parameters were determined: dominant peak frequency (Hz), acceleration (g) and amplitude of hand displacement (mm). Only the data of the more severely affected hand were used for the computation of results. Details of the recording and analysis procedures have been described elsewhere.9
At the completion of the accelerometric recordings, clinical evaluation of the postural tremor of the more involved hand (held in the same position used for accelerometric recording) was carried out. Additional evaluations included the patient's self-assessment of tremor severity during daily activities and tests of performance (hand-writing, drawing geometrical figures and tracing an Archimede's spiral). A score from 0 to 5 (maximum of tremor severity) was used for the rating of each parameter. For the tests of performance, the mean score derived from the rating of three independent investigators was used for the statistical analysis.
Measurements of pulse rate were obtained after a 10 min rest in the supine position and repeated after 1, 2 and 3 min of standing (the mean of these three values was used for the analysis). The inhibition of standing tachycardia was used as Calzetti, Findley, Perucca, Richens an approximate indication of cardiac/i-blockade. " Venous blood samples for the determination of serum propranolol or metoprolol levels were taken at the completion of the test. All tests were performed by the same investigator.
Serum propranolol and metoprolol assay Serum propranolol and metoprolol concentrations were measured by high pressure liquid chromatography according to a modification of the method of Nygard.12 Statistical analysis Statistical analysis of changes in tremor amplitude was carried out using the Wilcoxon's test for paired differences. Analysis of changes in pulse rate was carried out by means of Student's t test for paired data. Parameters determined during each active treatment period were compared with those determined after an equivalent period of placebo.
Results
TREMOR FREQUENCY AND AMPLITUDE DURING PLACEBO
The frequency of the dominant peak of hand tremor in the patients included in the study ranged from 4-2 to 10-0 Hz (median 7-2 Hz). In any individual patient the peak frequency of tremor varied somewhat on the two occasions of recording but when all patients were considered the difference was not statistically significant. The magnitude of hand tremor at the dominant frequency ranged from 00013 to 0-236 g (median 0-0096 g), which in terms of actual hand displacement corresponds to an amplitude of 0 006-2-7 mm (median 0-062 mm).
Two patients had placebo discontinued after a period of two weeks because tremor interfered seriously with their daily activities. On the other hand, four patients had during placebo treatment tremor amplitude below 0 02 mm, which is considered to be the upper limit of amplitude of physiological hand tremor in our laboratory (unpublished data). The (p < 0-02) respectively (comparison made with the placebo period). The reduction in tremor amplitude at the higher dosage did not differ from that observed at the lower dosage (fig 1) .
There was a trend for the amplitude of tremor to be lower during metoprolol treatment as compared to placebo (median reductions 13% at the 150 mg dosage and 32% at the 300 mg dosage), but the effect was not statistically significant. At neither of the two dosages used did the effect of metoprolol differ from that of placebo, irrespective of the method of assessment (figs 1 and 2 (fig 3) . The difference, however, was statistically significant only at the higher dosages of both metoprolol and propranolol. The degree of inhibition of standing tachycardia was similar for the two drugs.
Serum propranolol and metoprolol levels Serum concentrations of propranolol were found to vary from 21-0 to 164-0 ng/ml (median 44-0 ng/ml) and Calzetti, Findley, Perucca, Richens for the discrepancies between the results of the acute and of the chronic study may be related to differences in protocol. While in the acute study metoprolol was given as a single 150 mg dose 90 minutes before tremor assessment, in the chronic study the drug was given in divided daily administrations so that the individual dose taken before the assessment was smaller (50 or 100 mg). Moreover, in the chronic study the interval between drug intake and time of assessment (usually 120-180 min) could not be so rigidly standardised. Since metoprolol is rapidly absorbed, has a short half-life and does not accumulate during repeated administration, it is possible that the serum concentration of the drug at the time of tremor assessment was greater during the acute study. Since serum metoprolol concentrations in that study were not measured, this possibility cannot be excluded. In this regard, it is noteworthy that serum propranolol concentrations in the range of that obtained following a single oral dose (120 mg)'3 were achieved with 240 mg of the drug when administered chronically. However, since the pharmacokinetic differences between propranolol and metoprolol are not very marked, it is difficult to envisage how these could account for such a clear-cut differential response between these drugs in the two studies. Furthermore, the serum concentration of metoprolol (300 mg daily) at the time of assessment was sufficient to inhibit standing tachycardia to at least the same extent of that produced by the higher dosage of propranolol (fig 3) .
Another possibility that needs to be considered is that tolerance to the tremorolytic properties of the two fl-blockers developed. In the only controlled study' in which metoprolol was found to be effective, the drug was, however, given for no longer than one week. In our own patients, there was a tendency for the response to propranolol to be less marked after prolonged administration as compared to that observed following a single oral dose9 (at dosages producing similar serum drug concentrations). It is possible, however, that during chronic administration the effect of propranolol was mediated by some additional mode of action, not shared by metoprolol and to which tolerance did not develop.
It has been suggested that f I-selective adrenoceptor blocking drugs are less valuable than nonselective drugs in the treatment of essential tremor, 14 but this view has been questioned. 5 Since the cardioselectivity of metoprolol is at least partially lost at doses higher than 100-150 mg,'6 the more favourable long-term response to propranolol in our patients cannot be taken as sound evidence that the tremorolytic effect was related to blockade of 132- receptors.
Whatever the explanation for the disappointing response to prolonged administration of metoprolol, our results strongly suggest that in the absence of specific contraindications propranolol should be preferred to metoprolol in the treatment of essential tremor. 
